FLNA:BMV
Filana Therapeutics Inc
15,92 MXN
0,00%
(0,00) 1 D
5. okt., 12:05:31 GMT-6 · MXN
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for FLNA …
Markedsverdi
35,76 mill.
Snittvolum
0,00
Volum
0,00
52 u høy
56,00 MXN
52 u lav
15,92 MXN
Antall ansatte
19
Markedsverdi
35,76 mill.
Snittvolum
0,00
Volum
0,00
52 u høy
56,00 MXN
52 u lav
15,92 MXN
Antall ansatte
19
Nyhetssaker
Fra nettkilder og nyhetspartnere
https://www.dars.gov.et/
·
for 2 uker siden
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss of $0.22 Per Share Beats Estimates, Shares Rise 8.92% - Fiscal Year Earnings
Profil
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
Om Filana Therapeutics Inc
Administrerende direktør-
Ansatte19
Grunnlagt1998
HovedkontorAustin, Texas, USA
Sektor-
Nettstedpaintrials.com